Clinical Trials Directory

Trials / Completed

CompletedNCT05959213

Preoperative CA 19.9 Level Predicts Lymph Node Metastasis in Resectable Adenocarcinoma of the Head of the Pancreas.

Preoperative CA 19.9 Level Predicts Lymph Node Metastasis in Resectable Adenocarcinoma of the Head of the Pancreas: a Further Plea for Biological Resectability Criteria.

Status
Completed
Phase
Study type
Observational
Enrollment
2,034 (actual)
Sponsor
Fondazione Policlinico Universitario Campus Bio-Medico · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

In our multicenter retrospective study, preoperative CA 19.9 levels predicts the presence of lymph node metastasis at final histology in patients underwent pancreatoduodenectomy for pancreatic ductal adenocarcinoma .

Detailed description

A retrospective analysis have been conducted on more than 2.000 patients underwent pancreatoduodenectomy for pancreatic ductal adenocarcinoma radiologically resectable at the preoperative staging. Preoperatory levels of CA 19.9 were measured in order to identify a relation with nodal involvement at the pathological staging.

Conditions

Timeline

Start date
2000-01-01
Primary completion
2022-06-30
Completion
2023-03-01
First posted
2023-07-25
Last updated
2023-07-25

Source: ClinicalTrials.gov record NCT05959213. Inclusion in this directory is not an endorsement.

Preoperative CA 19.9 Level Predicts Lymph Node Metastasis in Resectable Adenocarcinoma of the Head of the Pancreas. (NCT05959213) · Clinical Trials Directory